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A COST–BENEFIT ANALYSIS OF GOWN USE IN
CONTROLLING VANCOMYCIN-RESISTANT ENTEROCOCCUS
TRANSMISSION: IS IT WORTH THE PRICE?
Laura A. Puzniak, PhD; Kathleen N. Gillespie, PhD; Terry Leet, PhD; Marin Kollef, MD; Linda M. Mundy, MD
Enterococci are the third most common pathogen
associated with nosocomial infections, accounting for 12%
of intensive care unit infections.1 The increasing preva-
lence of enterococcal infections is problematic due to lim-
ited treatment and eradication strategies. Furthermore,
the public health threat from vancomycin-resistant ente-
rococci (VRE) is more imminent given the recent detec-
tion of vancomycin-resistant Staphylococcus aureus
(VRSA).2-4 The presence of vanA in a clinical isolate of
VRSA from a host colonized with VRE suggests exchange
of genetic material between these gram-positive
pathogens.2
Hospital Infection Control Practices Advisory
Committee guidelines for controlling VRE include screen-
ing high-risk populations, using vancomycin appropriately,
educating medical staff, and implementing infection con-
trol procedures.5 Recommended infection control prac-
tices include the use of gloves and gowns with patients col-
onized or infected with drug-resistant pathogens.5 Despite
encouraging results for the efficacy of gown use, there is
ongoing debate over the cost versus benefit of requiring
gown use to prevent VRE transmission.6-15
Few studies have assessed the costs and benefits
associated with gown use.11-13 One study reported an
annual cost increase of $11,303 for gowns and gloves after
a VRE epidemic began.12 The authors concluded that pre-
venting a case of VRE bacteremia was worth the addition-
al cost for implementing isolation precautions. In contrast,
a study in a bone marrow transplant unit reported that dis-
continuing the use of gowns and shoe covers created a
$70,000 savings for the unit with no increase in infection
rates.11
Our prior work showed that requiring healthcare
workers and visitors to wear gowns when entering the
rooms of patients in a medical intensive care unit (MICU)
reduced the patients’ risk of VRE acquisition during peri-
ods of high VRE colonization pressure.13 The purpose of
this study was to determine the costs and benefits of this
enhanced infection control program aimed at reducing
VRE transmission.
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OBJECTIVE: To determine the net benefit and costs
associated with gown use in preventing transmission of van-
comycin-resistant Enterococcus (VRE).
DESIGN: A cost–benefit analysis measuring the net ben-
efit of gowns was performed. Benefits, defined as averted costs
from reduced VRE colonization and infection, were estimated
using a matched cohort study. Data sources included a step-down
cost allocation system, hospital informatics, and microbiology
databases.
SETTING: The medical intensive care unit (MICU) at
Barnes–Jewish Hospital, St. Louis, Missouri.
PATIENTS: Patients admitted to the MICU for more than
24 hours from July 1, 1997, to December 31, 1999.
INTERVENTIONS: Alternating periods when all health-
care workers and visitors were required to wear gowns and
gloves versus gloves alone on entry to the rooms of patients col-
onized or infected with VRE.
RESULTS: On base-case analysis, 58 VRE cases were
averted with gown use during 18 months. The annual net benefit
of the gown policy was $419,346 and the cost per case averted of
VRE was $1,897. The analysis was most sensitive to the level of
VRE transmission.
CONCLUSIONS: Infection control policies (eg, gown
use) initially increase the cost of health services delivery.
However, such policies can be cost saving by averting nosocomi-
al infections and the associated costs of treatment. The cost sav-
ings to the hospital plus the benefits to patients and their families
of avoiding nosocomial infections make effective infection con-
trol policies a good investment (Infect Control Hosp Epidemiol
2004;25:418-424).
ABSTRACT
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METHODS
Study Population
All patients staying more than 24 hours in a 19-bed
MICU at Barnes–Jewish Hospital from July 1, 1997, to
December 31, 1999, were eligible. All healthcare workers
and visitors were required to wear gowns and gloves on
entry into the rooms of patients colonized or infected with
VRE from July, 1, 1997, to June 30, 1998, and from July 1,
1999, to December 31, 1999. During the 12 months
between these two periods, gowns were not required. The
institutional review board committees of Saint Louis
University and Washington University approved this
study.
During the entire study period, all patients were
actively screened for VRE by collection of stool for cul-
tures or rectal swabs on admission, every 7 days, and at
discharge from the MICU. Per hospital protocol, stool
specimens sent for the detection of Clostridium dif ficile
toxin were also screened for VRE. For each patient with
VRE, a sign requiring contact precautions and an isolation
cart containing a dedicated stethoscope, a glass ther-
mometer, and gloves were placed at the entrance to the
patient’s room. Contact precautions were continued
unless a patient had two subsequent consecutive stool
surveillance specimens that tested negative. Gowns that
were fluid resistant and laundered after each use were
added to the isolation cart during the designated gown
periods.
A matched cohort study design was used to deter-
mine the attributable cost of VRE. Patients without VRE
from the same MICU population were matched to patients
with VRE by diagnosis-related group (DRG) code, Acute
Physiology and Chronic Health Evaluation (APACHE) II16
severity of illness score (± 2 points), and age (± 5 years).17
One patient without VRE was randomly selected for each
patient colonized with VRE when there were multiple
patients without VRE with the same matching criteria.
Two patients without VRE were randomly selected, using
the same matching criteria, for each patient with VRE bac-
teremia. Two matched controls were used to increase sta-
tistical power due to the small number of patients with
VRE bacteremia. Four patients colonized with VRE and
two patients with VRE bacteremia were excluded from the
study population because there was not a match of a
patient without VRE.
Clinical endpoints were obtained from the hospital’s
informatics system. These included MICU and hospital
lengths of stay, presence of nosocomial bacteremia due to
oxacillin-resistant S. aureus (ORSA) or Pseudomonas
aeruginosa, and presence of colitis or diarrhea associated
with C. dif ficile toxin. The three nosocomial pathogens
were used to determine whether the frequency of co-
infections was similar between patients with and patients
without VRE.
Costs
Overall costs for the VRE surveillance and infection
control program were estimated using the hospital’s step-
down cost allocation system, which recorded line-item
cost data per resource consumed and total cost per hospi-
tal admission. MICU costs were estimated from these
data by dividing the patient’s total hospitalization cost by
total days of hospitalization and then multiplying the quo-
tient by the patient’s total MICU-days. This data system
also provided hospital reimbursement data, type of insur-
ance, case mix index, and DRG. Medicare patients from
the study population were used to determine the average
non-reimbursed hospitalization cost by VRE status.
The cost for each isolation cart included all initial
supplies. In addition to the costs for gowns, the costs
resulting from staff time to comply with gown use were
estimated. Observational time trials were used to estimate
the time required for healthcare workers to retrieve, don,
doff, and properly dispose of gowns. On three separate
occasions, two unobtrusive observers measured the
amount of time required by 128 healthcare workers to
comply with the gown policy. Our observations showed
that the average worker needed 60 seconds (range, 35 to
95 seconds) to don and doff gowns, which was similar to
the amount of time needed for the same activities in anoth-
er study.18 To estimate the cost associated with excess
workload per VRE patient contact, the average time was
multiplied by the average registered nurse salary (exclud-
ing fringe benefits). Because a range of healthcare work-
ers entered a patient’s room, the average registered
nurse’s salary was used to approximate this cost.
Microbiology costs for each patient were obtained
from line-item reports from the hospital’s microbiology
database. Microbiology costs were inclusive of all related
testing costs (ie, materials, technician time, nursing time
for culture procurement, and overhead). Individualized
costs associated with contact precautions and surveil-
lance are listed in Table 1. All costs were reported in U.S.
dollars.
Decision Analysis
An event pathway of the study was constructed
showing VRE colonization and infection rates during this
30-month study period (Figure).13 Costs were allocated to
each arm based on actual resources consumed per
patient. Each patient with VRE, regardless of study peri-
od, was charged the costs for a cart, gloves, and hand
hygiene. During the gown period, patients with VRE were
charged additional costs for gowns and nursing time to
comply with the gown policy.
Benefits were measured as the number of VRE
cases and the MICU costs averted. The number of VRE
cases averted was estimated by multiplying the difference
in the VRE rates between the study periods by the num-
ber of patients in the gown period. The number of VRE
cases averted per 1,000 MICU-days was calculated by tak-
ing the number of cases averted and dividing it by the
total number of MICU patient-days in the gown period and
multiplying by 1,000. Averted attributable cost for the
gown period and net benefit of the gown policy19 were
computed as shown in equations 1 and 2, respectively.
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(1) averted attributable costgown = (attributable cost
of VRE colonization  annualized number of VRE colo-
nized cases averted) + (weighted mean attributable cost
of both diagnostic criteria of VRE bacteremia  annual-
ized number of VRE bacteremic cases averted)
(2) net benefit = averted attributable costgown -
(annualized isolation/surveillance costgown - isolation/sur-
veillance costno-gown)
The latter term in equation 2 measured the incre-
mental costs of the gown policy. Costs and benefits in the
gown period were annualized because the gown period
was 6 months longer than the no-gown period.
Sensitivity Analysis
A sensitivity analysis was performed varying sever-
al parameters related to the assumptions regarding the
number of gowns used, time required to don and doff
gowns, VRE transmission rates for this analysis, and cost
of materials. Our baseline estimate for the number of
gowns used was 100 gowns per patient per day. We used
the previously reported value of 60 contacts per day18 for
the lower limit and an equivalent difference, 140 contacts
per day, for the upper limit. The average number of VRE
cultures performed during the study was 2 per patient per
MICU stay. To adjust for variation in surveillance mecha-
nisms,20-23 we used 2 cultures as the baseline measure and
varied this measure between 1 and 4 cultures per MICU
stay. Because there were differences in cost between pos-
itive and negative cultures, we used the same proportion
of positive cultures as the original analyses when the para-
meter was changed to 4 cultures per patient. Because the
costs of isolation materials and laboratory testing can dif-
fer between hospitals and can increase due to inflation, we
altered the costs for these items by 20% in both directions.
As shown in the figure, the risks of both acquiring VRE
and developing bacteremia were lower in the gown peri-
od; therefore, we altered the probability of acquiring VRE
in the gown period from 40% to 100% of the probability of
acquiring VRE in the no-gown period to determine the net
benefit at varying levels of VRE transmission.
Statistical Analysis
Univariate statistics were obtained using SPSS soft-
ware (version 10.0; SPSS, Inc., Chicago, IL). Differences
in characteristics between patients with and patients with-
out VRE were identified using t tests for continuous
covariates and chi-square tests for categorical covariates.
A Decision Tree Add-In for Microsoft Excel was used for
the decision analysis (TreePlan, version 1.62; Microsoft
Corp., Redmond, WA).
RESULTS
Matched Cohort
Based on the matching criteria, patients with and
patients without VRE were closely matched. The mean
APACHE II scores were similar between patients colo-
nized with VRE and their matched controls and between
patients with VRE bacteremia and their matched controls
(22.0 vs 21.8 and 26.5 vs 26.3, respectively), as were the
mean ages (62.3 vs 62.2 years and 65.4 vs 64.0 years,
respectively). In addition, there were no significant differ-
ences in the frequency of co-infections between patients
TABLE 1
INDIVIDUALIZED COSTS ASSOCIATED WITH CONTACT PRECAUTIONS
AND VANCOMYCIN-RESISTANT ENTEROCOCCI SURVEILLANCE IN THE
MEDICAL INTENSIVE CARE UNIT
Cost
Variable Cost per Day
Gown $0.75 each $75.00
Gloves $0.07/pair $7.00
Hand hygiene $0.10/use $10.00
Nursing time to don and doff gowns $27.00/hour $45.00
Isolation cart set up (cost of initial $18.00 One-time
cart set up—bag of gowns,  cost
stethoscope, thermometer, and 
box of gloves)
VRE-negative test $12.13 Varies
VRE-positive test $24.29 Varies
VRE = vancomycin-resistant enterococci.
89
VRE colonization from admission culture
94 95%
VRE + on admission
8%
5
VRE infection from admission culture
5%
1164
Admission gown period
62%
1011
No acquisition
94%
1070
VRE - admission 55
VRE acquired colonization
92%
59 93%
VRE acquisition
6%
4
1872 VRE acquired infection
Enter
1 7%
79
VRE colonization from admission culture
88 90%
VRE + on admission
12%
9
VRE infection from admission culture
10%
708
Admission no gown period
38%
552
No acquisition
89%
620
VRE - admission 62
VRE acquired colonization
88%
68 91%
VRE acquisition
11%
6
VRE acquired infection
9%
FIGURE. An event pathway showing vancomycin-resistant enterococci
(VRE) colonization and infection rates from July 1, 1997, to December 31,
1999, for patients in the medical intensive care unit.
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colonized or infected with VRE and their matched con-
trols (data not shown).
Primary Outcomes
The length of MICU stay, length of hospital stay,
MICU costs, and hospital costs attributable to VRE were
less for patients colonized with VRE than for patients with
VRE bacteremia (Table 2). The length of MICU stay and
MICU costs attributable to VRE were less for patients
with VRE bacteremia who had one positive blood culture
than for such patients who had two or more positive cul-
tures, but the length of hospital stay and hospital costs
attributable to VRE were less for patients with VRE bac-
teremia who had two or more positive blood cultures than
for such patients who had one positive culture. However,
five patients in the latter group died while hospitalized.
Decision Analysis
The costs, benefits, and net benefit for the
enhanced infection control and VRE surveillance pro-
grams are listed in Table 3. The annualized costs were
$179,816 and $105,821 for the gown and no-gown periods,
respectively. Fifty-eight cases of VRE colonization, or 5.96
cases per 1,000 MICU-days, and 6 cases of VRE bac-
teremia, or 0.61 cases per 1,000 MICU-days, were averted
during the gown period. The incremental cost per case of
VRE colonization averted was $1,897. The annual net ben-
efit of the gown policy was $419,346.
Sensitivity Analysis
Several parameters were changed to determine the
impact of our four main assumptions on the net benefit of
gowns. The variation of 60 to 140 patient contacts yielded
net benefits of $388,664 and $450,017, respectively. The
variation of 1 and 4 cultures per patient resulted in net
benefits of $418,188 and $421,464, respectively. The varia-
tion in costs of labor and materials resulted in net benefits
of $406,488 and $435,426, respectively.
The results were most sensitive to the probability
of acquiring enteric VRE. Specifically, gowns are more
likely to impact transmission when there are high rates of
VRE colonization compared with when there are low
rates. At 40% of the no-gown transmission rate, the incre-
mental cost per case of VRE colonization averted was
$3,217 and the net benefit was $546,182. If the gowns did
not affect the rate of transmission (100%), there was a net
cost of $148,358, because no cases of VRE were averted.
The break-even point, or the point at which gowns
become cost-saving, was approximately 88% of the no-
TABLE 2
PRIMARY OUTCOMES STRATIFIED BY VANCOMYCIN-RESISTANT
ENTEROCOCCI STATUS FOR PATIENTS IN THE MEDICAL INTENSIVE
CARE UNIT
VRE-
Acquired VRE VRE
Colonized Bacteremia Bacteremia
Patients Patients* Patients†
Outcome (N = 113) (N = 17) (N = 5)
VRE attributable  4.0 18.9‡ 25.3‡,§
length of MICU 
stay, d
VRE attributable  8.3 38.2‡ 18.9‡,§
length of hospital 
stay, d
VRE attributable $7,873 $43,152‡ $58,207‡,
MICU cost
VRE attributable $11,989 $66,194‡ $44,632‡,§
hospital cost
VRE = vancomycin-resistant enterococci; MICU = medical intensive care unit.
*Patients with one positive VRE blood culture (includes VRE colonization on admission and
patients who acquired VRE).
†Patients with two positive VRE blood cultures or one positive blood culture and another site,
other than stool, positive (includes VRE colonization on admission and patients who acquired
VRE).
‡Versus VRE colonization (P < .01).
§Versus bacteremia with one positive VRE blood culture (P < .01).
Versus bacteremia with one positive VRE blood culture (P < .05).
TABLE 3
COSTS, BENEFITS, AND NET BENEFIT OF GOWN USE FOR PATIENTS
IN THE MEDICAL INTENSIVE CARE UNIT*
Gown Annualized No-Gown
Intervention Period Gown Period
Costs (N = 1,164) Period† (N = 708)
Gown costs (gowns, $116,040 $77,360 $0
nursing time to 
comply with gowns)
Cart, gloves, and hand $122,519 $81,679 $83,325
hygiene
Surveillance (VRE rectal $31,166 $20,777 $22,496
swabs and VRE stool 
samples)
Total cost of policies $269,725 $179,816 $105,821
Incremental cost of gown - $73,995 -
policy
VRE colonization cases 58 39 -
averted
VRE bacteremia cases 6 4 -
averted
Averted VRE colonization $456,634 $307,047 -
attributable MICU costs
Averted VRE bacteremia‡ $304,077 $186,294 -
attributable MICU costs
Total averted VRE $760,711 $493,341 -
attributable MICU costs
Net benefit - $419,346 -
VRE = vancomycin-resistant enterococci; MICU = medical intensive care unit.
*Additional data regarding VRE classification were obtained in procurement of cost and micro-
biology data for this study. Although the VRE classification was altered from previously report-
ed studies, the additional data did not alter the results of the previous study.13
†Costs were annualized because the gown and no-gown periods covered 18 and 12 months,
respectively.
‡Mean attributable cost of both diagnostic criteria for bacteremia.
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gown VRE transmission probability in this study. This
corresponds to the prevention of 7 cases of VRE colo-
nization.
DISCUSSION
The results of this cost–benefit analysis provide evi-
dence that gown use adds costs to the delivery of health
services in a MICU setting, but the benefits from averting
enteric VRE transmission outweigh those costs. Our prior
work demonstrated a protective effect of gowns for VRE
acquisition when VRE colonization pressure was high.13
In this analysis, the total attributable annual cost of the
gown policy was $73,995. The averted cost due to pre-
venting VRE colonization and bacteremia within the
MICU was $493,341, yielding a net cost savings of
$419,346. The attributable total hospital cost calculated for
one case of VRE colonization was $11,989. Thus, the cost
of the gown policy could be justified by averting 7 cases of
VRE colonization. Because VRE colonization increases
the risk for VRE bacteremia,24-28 which has much higher
costs, 7 cases is an over-estimate. The increased cost
associated with gown use needs to be considered relative
to the attributable length of stay, mortality, and costs
associated with VRE acquisition.29-40
In an era of cost containment, hospitals benefit from
focusing on effective ways to reduce non-reimbursable
costs.17,37-39 The hospital reimbursement structure, based
on the principal DRG codes, may not cover costs attribut-
able to iatrogenic problems, such as nosocomial infec-
tions, that contribute to prolonged stay.38,39 In this study,
the average cost not reimbursed from Medicare was sig-
nificantly higher for patients with VRE than for patients
without VRE (data not shown). From the perspective of
the hospital’s administration, this substantial difference
accentuates the costs attributable to VRE. By enhancing
resources for strategic infection control practices, hospi-
tal administrators can potentially reduce costs with infec-
tion control measures that reduce the rates of costly noso-
comial infections.
A strength of this study was the close matching of
patients who had VRE with patients who did not have VRE
by DRG codes, APACHE II scores, and age. By matching
on DRG codes, we expected to estimate the patient’s
length of stay and total hospital cost. The addition of
matching on APACHE II score allowed further control of
the complexity of illness within the DRG categories. As a
result, differences in length of stay and cost closely esti-
mated the attributable length of stay and cost associated
with VRE.17,37 The excess length of stay and costs attrib-
uted to nosocomial infections in our matched analysis
were similar to those reported in the literature for noso-
comial infections.29,36 There is, however, difficulty in com-
paring rates across studies due to the variation in method-
ology.17,37,38
There are several limitations to this study. The lim-
itation that biases the study toward finding gowns to be
cost-saving relates to the fact that the infection control
protocols for this study were already in place at this insti-
tution prior to the start of the study. Thus, costs for
study implementation, staff education, and staff familiar-
ity with the policy were not included in this study. If
these costs are substantial, then the cost savings would
be reduced. However, these costs would be incurred
once, whereas the benefits would continue to accrue
over time.
There are four limitations with uncertain or neutral
implications: generalizability, the lack of molecular typing,
the omission of blood culture costs, and the assumption of
no differences in patient contacts or care due to the use of
gowns. First, the findings from this study may not be gen-
eralizable to other settings. The unique characteristics of
this MICU include the routine performance of active VRE
surveillance, VRE endemnicity, and aggressive isolation
of patients colonized and infected with VRE, ORSA, and C.
dif ficile diarrheal disease. In this analysis, $53,662 was
associated with surveillance activities. Surveillance can
identify high rates of asymptomatic colonized patients and
serve as a proxy to initiate enhanced infection control
policies. Prevalence-based surveillance methods in hospi-
tals range from passive surveillance, where a stool speci-
men is collected for another clinical reason and then is
tested for VRE, to daily screening of patients for enteric
VRE.20-23 Depending on the existing VRE surveillance pol-
icy, the costs of implementing this intervention may vary.
Another unique feature of the study setting is that all
MICU patients had single rooms. Other studies have
shown that the proximity to a VRE-positive patient
increased the risk of acquisition.24,29,41 The physical plant
for this particular MICU may have contributed to lower
rates of VRE compared with intensive care units with
open ward settings containing multiple beds.
Second, we did not assess for confirmation of hori-
zontal transmission through molecular typing. Although
the conclusion regarding the effectiveness of gowns on
VRE acquisition would have remained unchanged, we
would have been potentially able to determine the number
of secondary cases of VRE generated from a primary case
of VRE and more accurately quantify the number of VRE
cases averted.
Third, because blood cultures identify a range of
pathogens and are not limited to VRE, the costs of blood
cultures were excluded from the analysis. Nonetheless,
the only way to detect VRE bacteremia is through a blood
culture. Notably, most (87%) of the patients in this study
had at least one blood culture. Because there were more
cases of VRE bacteremia in the no-gown period than in
the gown period, this may have underestimated the bene-
fit of gowns.
Fourth, we assumed that the number of patient
encounters and the quality of care provided did not differ
by the use of gowns in this study. Two randomized, con-
trolled trials suggest that the use of gowns did not inter-
fere with the physician–patient relationship, the duration
of visits, or the number of physical examinations per-
formed.41,42 However, a recent study found that patient
care suffered when patients were isolated.43 The
Vol. 25  No. 5 COST–BENEFIT ANALYSIS OF GOWNS 423
cost–benefit ratio was not very sensitive to the number of
contacts. However, the sensitivity analysis did not account
for differential numbers and lengths of patient contacts in
the two periods. This assumption may have biased the
results if there were more patient encounters during the
no-gown period than during the gown period, although
the direction of the bias is unclear. Decreased numbers of
patient contacts would decrease the opportunity for hori-
zontal transmission, but they might also be associated
with more adverse outcomes.
There are three limitations that bias the study
against finding gowns to be cost-saving. First, the addition
of costs attributed to excess workload due to the time it
takes nurses to don and doff gowns may have overesti-
mated the costs of the gown policy. The staff payroll is
unaffected by whether or not the MICU has a gown poli-
cy in place. Although the gown policy did not result in
overtime pay, donning and doffing gowns may have pre-
vented nurses from allocating time to other duties. From
an economics point of view, it was necessary to calculate
the opportunity costs of excess workload for the gowning
policy at the detriment of potentially overestimating the
cost of the policy.
Second, other benefits from surveillance and gown
use, such as averting colonization or infection at other
sites, decreasing the potential for horizontal transmission
of other pathogens, and decreasing the potential trans-
mission of resistant genes, were not quantified and thus
the benefit of gowns may have been underestimat-
ed.24,44,45
Finally, the cost analysis for this study was from the
perspective of the MICU and the hospital, not society. If a
societal perspective had been used, the magnitude of the
benefit would have been greater for averted cases of VRE
by including the benefits to patients from decreased mor-
bidity and mortality. The impact of these nosocomial
infections on patients and family members, missed days of
work, and time away from other activities were not deter-
mined.
Several studies now affirm the beneficial effects of
gown use in preventing and controlling the spread of
nosocomial pathogens.7,8,12-15 This secondary analysis of
the impact of gowns on VRE transmission confirms a
modest increased cost for the enhanced infection control
procedures associated with gown use that is offset by the
benefit of averting cases of enteric VRE. When the attrib-
utable hospital cost of VRE ranged from $11,989 to
$66,194 per patient and the increase in length of stay
ranged from 8.3 to 38.2 days, the extra expenditure of
$1,897 to prevent a case of VRE colonization yielded a net
savings to the hospital. In comparison with the costs of
other preventive health interventions (eg, immunization
programs), this cost associated with the prevention and
control of VRE is low given the anticipated benefits.46-53
Furthermore, with the recent reports of clinical cases of
VRSA, methods to control and prevent the spread of van-
comycin resistance remain a core component of strategic
hospital and public healthcare planning.2-4
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